Skip to main content
. 2019 Sep 10;10:2071. doi: 10.3389/fimmu.2019.02071

Figure 1.

Figure 1

dnDSA appearance in the 237 patients from the cohort. (A) Cumulative probability of dnDSA during patient follow-up. (B) Allograft survival (including recipient death) for patients exhibiting dnDSA after M12 was worse than that for patients who did not develop dnDSA during follow-up (log-rank test p < 0.0001).